CAMBRIDGE, Mass. (AP) – Vertex Pharmaceuticals Inc. has licensed two potential hepatitis C drugs from Alios BioPharma Inc.
Vertex said that it plans to start human testing of the two drugs later this year.
The company said the drugs, taken orally, appear to block an enzyme essential for replication of the hepatitis C virus. The virus can cause liver damage, cirrhosis, liver failure or cancer.
The Food and Drug Administration approved Vertex’s hepatitis C drug Incivek in May. Incivek it is expected to become a leading treatment for the disease.
Date: June 13, 2011
Source: Associated Press
Filed Under: Drug Discovery
